HSD17B13 and metabolic dysfunction-associated steatohepatitis: reported that the role of HSD17B13 rs72613567 in reducing the development of NASH and hepatic fibrosis may be influenced by the coexistence of other genetic variants as well as clinical risk factors including diabetes, obesity, and alcohol consumption.